Abstract

Motivation: Contrast agents allow a significant improvement of MRI performance. Resotran is a new iron oxide-based and biocompatible MRI contrast agent that is now commercially available in Europe, which still needs to be characterized in more detail. Goal(s): Classification of the performance of Resotran compared to Resovist. Approach: Analyzation and characterization with various spectroscopic and imaging methods. Results: Resotran shows a comparable performance to the former liver contrast agent Resovist. Furthermore, it was shown that Resotran is feasible as a tracer for the new imaging modality magnetic particle imaging (MPI). This is an important step towards paving the way for MPI in clinical routine. Impact: In this work it is shown that the new clinically approved contrast agent Resotran shows a comparable performance as the well-known contrast agent Resovist by a detailed comparison applying different spectroscopic characterization methods.